da Silva Castro Elaine, Alves Antunes Livia Azeredo, Revoredo Lobo Jonathas Felipe, Ratcliffe Norman Arthur, Borges Ricardo Moreira, Rocha Leandro, Burth Patricia, Fonte Amorim Lidia Maria
Molecular and Cellular Biology Department, Biology Institute, Fluminense Federal University, Niteroi, Brazil.
Specific Training Department, School of Dentistry, Fluminense Federal University, Nova Friburgo, Brazil.
Anticancer Agents Med Chem. 2018;18(3):323-334. doi: 10.2174/1871520617666170918130126.
This review summarizes the reported molecular mechanisms underlying the antileukemic property of Sesquiterpene Lactones (SLs). This systematic review was registered in the PROSPERO database and conducted following the PRISMA Statements. The MeSH terms, Sesquiterpenes, Lactones and Leukemia were used in four databases (Pubmed, Web of Science, Scopus and Bireme). There were 281 studies selected, but after exclusions, due to replication (n = 172) or not following PECOS criteria (n = 24), 148 studies remained. Of the 148 articles, only 22 were submitted to quality assessment and were scored in high level if more than two techniques, to elucidate antileukemic properties, were described, and then data were extracted. The studies mostly used human leukemia cell lines including primary and established cells, with or without chemotherapy resistance. The SLs used were obtained principally from plants. The antileukemic properties of SLs were extracted from 22 high level studies. They included cell death induction, mainly by apoptosis, as well as cell differentiation, cell cycle disruption, leukemia cancer stem cell growth inhibition and NF-κB pathway inhibition; the latter is a promising therapeutic target for lymphoid malignancies. We concluded that, in spite of the necessity of better toxicological profile characterization of SLs, the antileukemic properties of these compounds support the proposal that the SLs are promising candidates for the treatment of leukemia.
本综述总结了已报道的倍半萜内酯(SLs)抗白血病特性的分子机制。本系统综述已在PROSPERO数据库中注册,并按照PRISMA声明进行。在四个数据库(PubMed、Web of Science、Scopus和Bireme)中使用了主题词“倍半萜类、内酯类和白血病”。共筛选出281项研究,但排除重复研究(n = 172)或不符合PECOS标准的研究(n = 24)后,还剩148项研究。在这148篇文章中,只有22篇接受了质量评估,如果描述了两种以上阐明抗白血病特性的技术,则被评为高水平,然后提取数据。这些研究大多使用人白血病细胞系,包括原代细胞和已建立的细胞系,有或无化疗耐药性。所使用的SLs主要从植物中获得。从22项高水平研究中提取了SLs的抗白血病特性。它们包括主要通过凋亡诱导细胞死亡,以及细胞分化、细胞周期破坏、白血病癌干细胞生长抑制和NF-κB通路抑制;后者是淋巴恶性肿瘤一个有前景的治疗靶点。我们得出结论,尽管有必要更好地表征SLs的毒理学特征,但这些化合物的抗白血病特性支持了SLs有望成为治疗白血病候选药物的提议。